Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Enrolling by invitation

Conditions studied: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis

In brief

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Key facts

Study ID

NCT05697861

Run by

Intellia Therapeutics

People needed

72

Starts

2023-07-10

Expected to finish

2038-03-01

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.
• A subject has provided informed consent for the LTFU study.

You may not qualify if…

• None

Where it is running

• Clinical Trial Site — Paris, France
• Clinical Trial Site — Auckland, New Zealand
• Clinical Trial Site — Umeå, Sweden
• Clinical Trial Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.